Figure 1.
![Figure 1. Overallsurvival (OS) of 70 multi-mutated KIT D816V+ advanced systemic mastocytosis patients depending on number of mutated genes in SRSF2/ASXL1/RUNX1 (S/A/R) gene panel. HR [hazard ratio 95% confidence interval (CI)].](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/126/23/10.1182_blood.v126.23.349.349/3/349fig01.jpeg?Expires=1749033398&Signature=t4pEftCvK-gZEGv4BUvxeUVA0pnFU0~JJ2lRGgXIYvEwwHNOLHZzKIT-WlokBtNAVGpfyjCd7BdX8IBnphMSZvsrq2SkvGjihkNmg8sLiaorkUi13WYqyPgI6PLI6qUsf0lA2cUTK0SoKQUtmtXooFxAaqU9v0zEQ2lKH9q6W4I8wu5MXRB4DCFjvwx3amLqe8nE2g-XKkxgKENtoz1uoY9RCLGhr8b31xglwx0slQI1IABGCOC956N72hrXzElmBRpKKR3V4Ak2Q-TftIXCpgZajBfbjgm80Se1-xYHl4x0pRBky2NFm27Jb-Ss-1DIvYUz6p0AxACw5pku7bYQ6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Overallsurvival (OS) of 70 multi-mutated KIT D816V+ advanced systemic mastocytosis patients depending on number of mutated genes in SRSF2/ASXL1/RUNX1 (S/A/R) gene panel. HR [hazard ratio 95% confidence interval (CI)].
Overallsurvival (OS) of 70 multi-mutated KIT D816V+ advanced systemic mastocytosis patients depending on number of mutated genes in SRSF2/ASXL1/RUNX1 (S/A/R) gene panel. HR [hazard ratio 95% confidence interval (CI)].
